J&J's Regranex Ups Cancer Mortality Risk: FDA
The U.S. Food and Drug Administration has added its most serious warning to Johnson & Johnson's Regranex after a study indicated that although diabetics who use large amounts of the foot...To view the full article, register now.
Already a subscriber? Click here to view full article